News Bayer CEO confident firm can cope with Xarelto hit Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
News AZ backs up threat of manufacturing shift from Europe AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
News AbbVie makes its tariffs-driven investment play AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration.
News MSD has gauged its financial hit from Trump tariffs MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
